Curium, a nuclear medicine company, has acquired Nucleis, a specialist in GMP manufacturing and distribution of PET radiopharmaceutical drugs.

Founded in 2017 as a spin-off from the University of Liège, Nucleis manufactures and distributes FDG in the Benelux region and offers CDMO services to third-party nuclear medicine players to produce innovative tracers.

This acquisition marks a milestone in Curium’s strategic growth in the PET segment, reinforcing its commitment to nuclear medicine innovation and ensuring greater accessibility to cutting-edge PET diagnostics for patients across Europe.

The acquisition will add manufacturing capacity to meet the growing demand for F-18 tracers and it will reinforce the reliability of Curium’s supply chain, ensuring consistent delivery of critical radiopharmaceuticals to healthcare providers and patients across the Benelux region.

Through this acquisition, Curium will accelerate the development of life-changing diagnostics in oncology, neurology, and cardiology. The company will expand production of radiotracers by adding Curium’s proprietary tracers to Nucleis’ portfolio and strengthening partnerships with CDMO customers.

Benoit Woessmer, CEO of Curium EU, commented, “We are thrilled to welcome Nucleis into the Curium family. This acquisition is an additional step in expanding our PET footprint and strengthening our capabilities in the European nuclear medicine market. By combining our resources with the Nucleis team, we will further enhance the availability of high-quality PET diagnostics for patients.”

Fabrice Giacomelli, Former CEO of Nucleis, added, “Joining Curium marks an exciting new chapter for Nucleis. We will benefit from Curium’s expertise and infrastructure to accelerate the development and delivery of next-generation PET tracers, benefiting patients and healthcare providers alike.”

More Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.